Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.06
-0.01 (-0.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $52.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.8B
P/E
N/A
•EV/EBITDA
32.0x
↑ROE
-1.8%
↓Gross Margin
24.4%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.7%
FCF CAGR
—
FCF margin
-7.2%
FCF / Net income
1.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.86B · net income $-91.1M · FCF $-134.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.86B | $1.86B | $1.94B | $2.17B | $2.70B |
| Net Income | $-91.1M | $-91.1M | $-330.3M | $-420.1M | $88.0M |
| EBITDA | $284.3M | $284.3M | $34.7M | $-63.9M | $473.9M |
| EPS | -0.06 | -0.06 | -0.21 | -0.26 | 0.05 |
| Gross Margin | 24.4% | 24.4% | 26.7% | 14.0% | 26.6% |
| Operating Margin | -0.6% | -0.6% | 2.1% | -7.7% | 5.6% |
| Net Margin | -4.9% | -4.9% | -17.0% | -19.3% | 3.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.24 | 0.19 | 0.16 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-134.1M | $-134.1M | $52.7M | $87.5M | $-63.3M |
| Returns | |||||
| ROE | -1.8% | -1.8% | -6.4% | -7.5% | 1.4% |
| Valuation | |||||
| P/E | — | — | — | — | 147.00 |
| EV/EBITDA | 32.04 | 32.04 | 215.88 | — | 26.27 |
| P/B | 1.83 | 1.83 | 1.51 | 2.05 | 2.12 |
| Growth & Yield | |||||
| Revenue Growth | -4.0% | -4.0% | -10.7% | -19.7% | — |
| EPS Growth | 71.4% | 71.4% | 19.2% | -620.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.21 → -0.06
Residual
+14.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.